ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0082

Mortality Prediction of Serum Neutrophil Gelatinase-Associated Lipocalin in Patients Requiring Continuous Renal Replacement Therapy

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Chung, Byung ha, Seoul Saint Mary's Hospital, Seocho-gu, Seoul, Korea (the Republic of)
  • Park, Yohan, Seoul Saint Mary's Hospital, Seocho-gu, Seoul, Korea (the Republic of)
  • Kim, Hyung Duk, Seoul Saint Mary's Hospital, Seocho-gu, Seoul, Korea (the Republic of)
  • Ko, Eun jeong, Seoul Saint Mary's Hospital, Seocho-gu, Seoul, Korea (the Republic of)
  • Ban, Tae Hyun, Eunpyeong Saint Mary's Hospital, Eunpyeong-gu, Seoul, Korea (the Republic of)
  • Park, Cheol Whee, Seoul Saint Mary's Hospital, Seocho-gu, Seoul, Korea (the Republic of)
  • Yang, Chul Woo, Seoul Saint Mary's Hospital, Seocho-gu, Seoul, Korea (the Republic of)
Background

We investigated whether serum neutrophil gelatinase-associated lipocalin (NGAL) can predict mortality in patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT).

Methods

This study enrolled 169 patients who underwent serum NGAL testing at CRRT initiation from June 2017 to January 2019. The predictive power of serum NGAL level for 28-day mortality was compared to the Acute Physiology and Chronic Health Evaluation-II (APACHE-II) score and Sequential Organ Failure Assessment (SOFA) score via area under the receiver operating characteristic curve (AuROC) value.

Results

There were 55 survivors and 114 non-survivors at 28 days post-CRRT initiation. Median serum NGAL level was significantly higher in the non-survivor group than in the survivor group (743.0 vs. 504.0 ng/mL, P=0.003). The AuROC value of serum NGAL level was 0.640, which was lower than APACHE-II score and SOFA score values (0.767 and 0.715, respectively). However, in the low APACHE-II score group (<27.5), AuROC value of serum NGAL was significantly increased (0.698), and it was an independent risk factor for 28 day-mortality (hazard ratio 2.405, 95% confidence interval (1.209-4.783), P=0.012).

Conclusion

In patients with AKI requiring CRRT, serum NGAL levels may be useful for predicting short-term mortality in those with low APACHE-II scores.

Figure 1. Predictive value for 28-day mortality of serum NGAL level, APACHE-II score, and SOFA score in low APACHE-II score group

Funding

  • Government Support - Non-U.S.